NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.31
Index: ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.28

25 Jun
2026

0.040

OPEN

$3.25

1.23%

HIGH

$3.30

251,292

LOW

$3.23

TARGET
$3.80 15.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 5.9 3.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 13.5% - 33.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 77.7 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx5.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx203.5 M
Book Value Per Share xxxxxxxxxxxxxxx72.8
Net Operating Cash Flow xxxxxxxxxxxxxxx22.6 M
Net Profit Margin xxxxxxxxxxxxxxx8.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx8.35 %
Return on Invested Capital xxxxxxxxxxxxxxx7.89 %
Return on Assets xxxxxxxxxxxxxxx6.08 %
Return on Equity xxxxxxxxxxxxxxx8.35 %
Return on Total Capital xxxxxxxxxxxxxxx6.54 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx17.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx20 M
Total Debt xxxxxxxxxxxxxxx23 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx155 M
Price To Book Value xxxxxxxxxxxxxxx4.58

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx5.1 M
Capex % of Sales xxxxxxxxxxxxxxx2.52 %
Cost of Goods Sold xxxxxxxxxxxxxxx55 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx134 M
Research & Development xxxxxxxxxxxxxxx29 M
Investments - Total xxxxxxxxxxxxxxx1 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

25/02/2026

3

Upgrade to Hold from Sell

$3.60

9.76%

Nanosonics reported 1H26 revenues of $102.2m (consensus of $105m), up 9% year on year, while earnings of $8.5m were modestly ahead of consensus but only in line with the prior first half.

The US remained the powerhouse for revenue growth, Bell Potter notes, generating double digit percentage growth across capital sales and consumables

However, total revenues failed to exceed the prior sequential period for the first time since the end of the covid period due to the combination of currency headwinds and slowing consumables sales.

Target falls to $3.60 from $4.10, but Bell Potter upgrades to Hold from Sell based on valuation. In the broker's view the stock is oversold and the current market price represents a reasonable entry point.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.20 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

04/03/2026

1

Buy

$5.55

69.21%

Nanosonics' 1H26 missed on revenue but it was nothing dramatic, in Canaccord Genuity's view. Earnings were ahead, FY26 guidance is maintained and CORIS is launching (controlled market release underway).

At current share price, the Trophon-only business appears to be trading at a -15% discount to international med-tech peers. Canaccord can see how CORIS can make Nanosonics seem optically expensive, until it too becomes earnings-generative.

Target rises to $5.55 from $5.43, Buy retained.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.00 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

Latest Medical Equipment & Devices News

1
Shortages Chip Away At ResMed’s Big Break

Mar 30 2022 - Australia
2
Opportunity for Fisher & Paykel Healthcare

Mar 25 2022 - Australia
3
Distribution Anxiety For Nanosonics

Feb 10 2022 - Australia
4
Brokers Awake To ResMed’s Potential

Jan 31 2022 - Australia
5
Covid Benefits F&P Healthcare, For Now

Dec 06 2021 - Australia
6
Will Shortages Limit Upside For ResMed?

Nov 01 2021 - Australia
7
Nanosonics Unveils Its New Product

Aug 26 2021 - Australia
8
Pro Medicus: Opportunity Awaits

Aug 24 2021 - Technicals
9
Breakout For Cochlear

Aug 10 2021 - Technicals
10
Will ResMed’s Market Share Gains Last?

Aug 09 2021 - Australia